Real-time Estimate
Cboe BZX
15:27:35 2024-05-24 EDT
|
5-day change
|
1st Jan Change
|
1.465
USD
|
-0.34%
|
|
-15.91%
|
+124.24%
|
Fiscal Period: December |
2021
|
2022
|
---|
Capitalization
1 |
105.9
|
110.2
|
Enterprise Value (EV)
1 |
106
|
111.4
|
P/E ratio
|
-2.8
x
|
-10.5
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
EV / Revenue
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
EV / FCF
|
4,743,213
x
|
20,859,169
x
|
FCF Yield
|
0%
|
0%
|
Price to Book
|
-26.2
x
|
-16.8
x
|
Nbr of stocks (in thousands)
|
10,600
|
10,600
|
Reference price
2 |
9.990
|
10.40
|
Announcement Date
|
22-04-11
|
23-03-31
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
EBIT
1 |
-0.232
|
-1.652
|
-62.34
|
-16.12
|
Operating Margin
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-0.232
|
-1.653
|
-62.34
|
-17.36
|
Net income
1 |
-0.232
|
-1.653
|
-62.34
|
-17.36
|
Net margin
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0133
|
-0.0947
|
-3.565
|
-0.9921
|
Free Cash Flow
|
-
|
-
|
22.33
|
5.285
|
FCF margin
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-05
|
21-03-05
|
22-04-11
|
23-03-31
|
Fiscal Period: December |
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
-
|
-
|
-
|
EBITDA
|
-5.223
|
-2.68
|
-
|
EBIT
1 |
-5.223
|
-2.68
|
-2.655
|
Operating Margin
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-67.4
|
-13.03
|
-14.09
|
Net income
1 |
-67.4
|
-13.03
|
-14.09
|
Net margin
|
-
|
-
|
-
|
EPS
2 |
-2.720
|
-0.4900
|
-0.5300
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
23-05-24
|
23-08-14
|
24-04-15
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
|
-
|
-
|
0.12
|
1.19
|
Net Cash position
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
22.3
|
5.28
|
ROE (net income / shareholders' equity)
|
-
|
156%
|
1,459%
|
199%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-16,759%
|
-1,049%
|
Assets
1 |
-
|
-
|
0.372
|
1.655
|
Book Value Per Share
2 |
-0.0100
|
-0.1100
|
-0.3800
|
-0.6200
|
Cash Flow per Share
|
-
|
-
|
0
|
0
|
Capex
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-05
|
21-03-05
|
22-04-11
|
23-03-31
|
|
1st Jan change
|
Capi.
|
---|
| +122.73% | 53.71M | | +10.79% | 116B | | +11.65% | 106B | | -6.20% | 23.89B | | -2.88% | 21.58B | | -11.42% | 18.96B | | -13.41% | 16.33B | | -40.50% | 16.96B | | +6.64% | 14.14B | | +31.84% | 12.02B |
Bio Therapeutic Drugs
|